CN102791282A - 可口服给予的含有胰岛素的药物制剂 - Google Patents

可口服给予的含有胰岛素的药物制剂 Download PDF

Info

Publication number
CN102791282A
CN102791282A CN201080038764XA CN201080038764A CN102791282A CN 102791282 A CN102791282 A CN 102791282A CN 201080038764X A CN201080038764X A CN 201080038764XA CN 201080038764 A CN201080038764 A CN 201080038764A CN 102791282 A CN102791282 A CN 102791282A
Authority
CN
China
Prior art keywords
insulin
pharmaceutical formulation
amino
casein
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201080038764XA
Other languages
English (en)
Chinese (zh)
Inventor
S·佐尔坦
P·巴纳
N·卓则夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CERA-MED KFT
Original Assignee
CERA-MED KFT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CERA-MED KFT filed Critical CERA-MED KFT
Publication of CN102791282A publication Critical patent/CN102791282A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201080038764XA 2009-08-03 2010-08-02 可口服给予的含有胰岛素的药物制剂 Pending CN102791282A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0900482A HUP0900482A2 (en) 2009-08-03 2009-08-03 Pharmaceutical formulation for oral administration
HUP0900482 2009-08-03
PCT/IB2010/053499 WO2011015984A1 (en) 2009-08-03 2010-08-02 Orally administerable pharmaceutical preparation containing insulin

Publications (1)

Publication Number Publication Date
CN102791282A true CN102791282A (zh) 2012-11-21

Family

ID=89989155

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080038764XA Pending CN102791282A (zh) 2009-08-03 2010-08-02 可口服给予的含有胰岛素的药物制剂

Country Status (15)

Country Link
US (1) US20120129769A1 (enExample)
EP (1) EP2461820A1 (enExample)
JP (1) JP2013501043A (enExample)
KR (1) KR20120088660A (enExample)
CN (1) CN102791282A (enExample)
AU (1) AU2010280418B2 (enExample)
BR (1) BR112012002413A2 (enExample)
CA (1) CA2769620A1 (enExample)
HU (1) HUP0900482A2 (enExample)
IL (1) IL217856A0 (enExample)
MX (1) MX2012001461A (enExample)
RU (1) RU2012109006A (enExample)
UA (1) UA106506C2 (enExample)
WO (1) WO2011015984A1 (enExample)
ZA (1) ZA201201519B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111065749A (zh) * 2017-06-28 2020-04-24 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） 用于确定发展1型糖尿病的风险的方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013003824A1 (en) * 2011-06-29 2013-01-03 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
KR20240171428A (ko) 2023-05-30 2024-12-09 (주)네오비젼 당뇨병 치료를 위한 약물 방출 제어가 가능한 약물 전달용 콘택트렌즈

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127535A2 (en) * 1983-05-23 1984-12-05 Hadassah Medical Organization Pharmaceutical compositions containing insulin
JPH06172199A (ja) * 1992-12-07 1994-06-21 Tsumura & Co ペプチド類経鼻投与用組成物
CN1116629A (zh) * 1994-06-16 1996-02-14 伊莱利利公司 单体胰岛素类似物制剂
CN101062408A (zh) * 2006-04-27 2007-10-31 深圳市隆阳生物科技有限公司 口服胰岛素复合制剂及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172814A (en) 1962-04-06 1965-03-09 Jr Edgar A Ferguson Oral blood sugar lowering compositions
JPS5428807A (en) 1977-08-09 1979-03-03 Hiroyuki Sumi Oral insulin
EP0351651B1 (en) 1988-07-21 1993-09-15 F. Hoffmann-La Roche Ag Insulin preparation
ES2085656T3 (es) 1991-12-05 1996-06-01 Alfatec Pharma Gmbh Forma de administracion peroral de medicamentos peptidicos, en particular insulina.
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
EP0803255A4 (en) * 1994-06-03 1999-06-30 Tsumura & Co MEDICINAL COMPOSITION
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5970193A (en) 1996-10-24 1999-10-19 Nortel Networks Corporation Data communications structures relating to data shelf configurations
JP2002512607A (ja) 1997-04-02 2002-04-23 パーデュー・リサーチ・ファウンデーション タンパク質の経口デリバリー法
JP2002531518A (ja) 1998-12-04 2002-09-24 プロヴァリス・ユーケー・リミテッド インスリン含有医薬組成物
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
EA200501422A1 (ru) 2003-03-04 2006-04-28 Дзе Текнолоджи Девелопмент Компани Лтд. Длительнодействующая инъецируемая композиция инсулина и способы её изготовления и применения
JP5103748B2 (ja) * 2005-02-16 2012-12-19 東レ株式会社 医薬組成物
EP1933862B1 (en) * 2005-09-06 2014-03-26 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
JP2008266179A (ja) * 2007-04-19 2008-11-06 Fujifilm Corp 経肺用組成物
WO2008145728A1 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
AU2009283821B2 (en) * 2008-08-18 2014-05-29 Entera Bio Ltd. Methods and compositions for oral administration of proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127535A2 (en) * 1983-05-23 1984-12-05 Hadassah Medical Organization Pharmaceutical compositions containing insulin
JPH06172199A (ja) * 1992-12-07 1994-06-21 Tsumura & Co ペプチド類経鼻投与用組成物
CN1116629A (zh) * 1994-06-16 1996-02-14 伊莱利利公司 单体胰岛素类似物制剂
CN101062408A (zh) * 2006-04-27 2007-10-31 深圳市隆阳生物科技有限公司 口服胰岛素复合制剂及其制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111065749A (zh) * 2017-06-28 2020-04-24 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） 用于确定发展1型糖尿病的风险的方法
CN111065749B (zh) * 2017-06-28 2024-06-28 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） 用于确定发展1型糖尿病的风险的方法

Also Published As

Publication number Publication date
WO2011015984A1 (en) 2011-02-10
IL217856A0 (en) 2012-03-29
UA106506C2 (uk) 2014-09-10
BR112012002413A2 (pt) 2016-03-01
JP2013501043A (ja) 2013-01-10
AU2010280418A1 (en) 2012-03-22
HUP0900482A2 (en) 2011-03-28
US20120129769A1 (en) 2012-05-24
AU2010280418B2 (en) 2015-04-09
RU2012109006A (ru) 2013-09-10
HU0900482D0 (en) 2009-10-28
EP2461820A1 (en) 2012-06-13
KR20120088660A (ko) 2012-08-08
ZA201201519B (en) 2013-05-29
CA2769620A1 (en) 2011-02-10
MX2012001461A (es) 2012-05-22

Similar Documents

Publication Publication Date Title
US12311051B2 (en) Methods and compositions for oral administration
CN101547702B (zh) 用于口服给药蛋白质的方法和组合物
RU2566063C2 (ru) Композиции и способы перорального введения эксенатида
US20110311621A1 (en) Pharmaceutical compositions and methods of delvery
JPH11508606A (ja) 経口用ペプチド薬剤
CN102791282A (zh) 可口服给予的含有胰岛素的药物制剂
JP2013501043A5 (enExample)
CN104857505A (zh) 用于口服给予蛋白质的方法和组合物
KR20170093332A (ko) 경구투여가능한 인슐린 함유 약제학적 조성물
HK40039520A (en) Methods and compositions for oral administration of proteins
HK1158938B (en) Methods and compositions for oral administration of proteins
HK1158938A (en) Methods and compositions for oral administration of proteins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121121